View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Haselmeier
18 May 2016

Haselmeier and Merck Launch Second Version of Axis-D Pen Injector

Following approval by the European Medicines Agency (EMA), GONAL-f® 2.0 was launched by Haselmeier and Merck following its original release in 2011.

The new version is based on Haselmeier’s disposable, multi-use pen Axis-D platform, which has been enhanced to make it easier to hold. It also has a larger screen for improved readability.

These changes will help patients to clearly view their pre-set dosage, reassuring them that they have taken the correct amount. This is complemented further by a graduated scale on the transparent cartridge.

Merck’s original design features have been retained and improved, including dosing accuracy and individual dosing.

Haselmeier’s key account manager Klaus Schmid comments: "We see this as an important next step in the future partnership with Merck to bring technology and life cycle management evolution to the existing portfolio of Merck devices."

The company’s strategic product manager Stefan Gaul adds: "We are happy about the opportunity to support Merck with the development of the next generation of GONAL-f® pen design. We are convinced that this new pen will be appreciated by patients, due to its simple and convenient use, as well as its sophisticated design."

Type 2 diabetes is a global health problem. According to expert estimates, the number of patients worldwide will increase by 48% by 2045.
The D-Flex injection pen can do more than previous pens. D-Flex can be configured for several fixed-dose values and is thus a variable fixed-dose pen.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology